Market Research Report
Cathepsin S - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||363132|
|Published||Content info||33 Pages
Delivery time: 1-2 business days
|Cathepsin S - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 33 Pages||
According to the recently published report 'Cathepsin S - Pipeline Review, H1 2020'; Cathepsin S (CTSS or EC 188.8.131.52) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Cathepsin S (CTSS or EC 184.108.40.206) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.
The report 'Cathepsin S - Pipeline Review, H1 2020' outlays comprehensive information on the Cathepsin S (CTSS or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cathepsin S (CTSS or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology, Infectious Disease and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.